GSK plc announced on December 16, 2024, that its drug Jemperli (dostarlimab) received a positive opinion from the CHMP for expanded approval to treat all adult patients with primary advanced or recurrent endometrial cancer, based on significant survival data from the RUBY trial, with full approval expected in Q1 2025.